Markets:

Overview

News

Currencies

International

Treasuries

BioAge Labs, Inc. - Common Stock (NQ:BIOA)

16.07 -0.30 (-1.83%)

Streaming Delayed Price Updated: 2:23 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about BioAge Labs, Inc. - Common Stock

< Previous 1 2 Next >

A Healthcare Fund Just Made Bitgo Its Biggest Bet ↗

May 19, 2026

Bitgo Holdings provides digital asset infrastructure and custody services for institutional clients, supporting secure management at scale.

Via The Motley Fool

Topics Regulatory Compliance

BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials ↗

May 08, 2026

BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across...

Via MarketBeat

Tuesday's after hours session: top gainers and losers ↗

January 06, 2026

Via Chartmill

2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole ↗

December 13, 2025

Don't be too quick to jump on this biotech bandwagon.

Via The Motley Fool

BioAge Labs Inc (NASDAQ:BIOA) Reports Q3 2025 Earnings with Significant Revenue Beat ↗

November 06, 2025

BioAge Labs reported a mixed Q3 2025, beating revenue estimates by 94% with a narrower EPS loss. The clinical-stage biotech advanced its lead drug, BGE-102, with cash runway through 2029.

Via Chartmill

Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy ↗

November 05, 2025

The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.

Via The Motley Fool

Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? ↗

October 29, 2025

This stock has caught fire after some recent events, but how long will that last?

Via The Motley Fool

BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? ↗

October 26, 2025

The clinical-stage biotech is working on a new type of weight management drug.

Via The Motley Fool

Here are the top movers in Thursday's session. ↗

October 23, 2025

Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 23, 2025

Via Benzinga

Which stocks are moving on Thursday? ↗

October 23, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

These stocks are gapping in today's session ↗

October 23, 2025

The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

October 23, 2025

Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 23, 2025

Via Benzinga

This Badger Meter Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗

October 22, 2025

Via Benzinga

BioAge Labs (BIOA) Q2 Revenue Hits $2.4M ↗

August 06, 2025

Via The Motley Fool

Topics Intellectual Property

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 09, 2024

Via Benzinga

Crude Oil Gains 2%; BioAge Labs Shares Plunge ↗

December 09, 2024

Via Benzinga

Nasdaq Down Over 100 Points; US Wholesale Inventories Rise By 0.2% ↗

December 09, 2024

Via Benzinga

Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday ↗

December 09, 2024

Via Benzinga

BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

December 09, 2024

Via Benzinga

Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns ↗

December 09, 2024

BioAge Labs halts STRIDES Phase 2 trial of azelaprag after liver enzyme elevations, plans further analysis with updates expected in Q1 2025.

Via Benzinga

Topics Initial Public Offering

Why Interpublic Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗

December 09, 2024

Via Benzinga

Self-Driving Startup Pony.ai Files For U.S. IPO ↗

October 20, 2024

Self-driving startup Pony.ai of China filed for an IPO in the U.S. this week. Meanwhile, four companies -- Springview Holdings, Oriental Rise Holdings, PTL Limited, and Samfine Creation Holdings Group...

Via Talk Markets

Topics Initial Public Offering

Prediction: These 2 Stocks Could Soar in 2025 ↗

October 17, 2024

The key word here is "could."

Via The Motley Fool

GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom ↗

October 13, 2024

The future of the weight loss market might not revolve around GLP-1 drugs.

Via The Motley Fool

Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock ↗

October 12, 2024

BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.

Via The Motley Fool

Topics Initial Public Offering

2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now ↗

October 07, 2024

One of these businesses is a risky play, but the other is very likely to succeed.

Via The Motley Fool

3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October ↗

October 05, 2024

There's a chance that its lead candidate could become one of the top drugs ever.

Via The Motley Fool

This IPO Biotech Stock Could Be the Next Eli Lilly ↗

October 03, 2024

BioAge has its eyes on a handful of truly gargantuan markets.

Via The Motley Fool

Topics Initial Public Offering

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.